logo

Indoco Remedies Q2FY26 Results: Revenue Rises 9.6% YoY to ₹47,183 Lakh; Net Loss At ₹921 Lakh

By Shishta Dutta | Published at: Nov 6, 2025 03:51 PM IST

Indoco Remedies Q2FY26 Results: Revenue Rises 9.6% YoY to ₹47,183 Lakh; Net Loss At ₹921 Lakh
Open Free Demat Account

By signing up I certify terms, conditions & privacy policy

Mumbai, November 6: Indoco Remedies Limited has announced its financial results for the quarter ending September 30, 2025. It reported a rise of 9.6% YoY in its revenue to ₹47,183 lakh, along with a lower loss of ₹921 lakh.

Indoco Remedies Limited (NSE: INDOCO, BSE: 532612) is an Indian company that manufactures pharmaceutical Formulations. It was established in 1947, and is headquartered in Mumbai, Maharashtra.

Indoco Remedies Q2FY26 Results

For Q2FY26, the company’s consolidated Revenue from Operations rose 9.6% year-on-year (YoY), reaching ₹47,183 lakh. The Total Income grew by 11.8% to ₹48,543 lakh. EBITDA increased by 12.1% to ₹6,375 lakh. However, the company reported a Net Loss of ₹921 lakh for the quarter. This was a lower loss compared to the net loss of ₹1,001 lakh in the same quarter last year.

For the first half of the fiscal year (H1FY26), the consolidated Revenue from Operations increased to ₹90,270 lakh, up from ₹85,195 lakh last year. However, the Net Loss was at ₹4,555 lakh, compared to a loss of ₹820 lakh in the first half of the previous year. EPS for H1FY26 stood at (₹4.94). The India business contributed 64.4% of revenue, and grew by 4.7% over the previous quarter to ₹30,370 lakh. The Outside India business contributed 35.6% of revenue and grew by 19.7%, reaching ₹16,813 lakh.

Shares Fall By 1.77% to ₹260.15

As of 3:00 PM, Indoco Remedies’ share price was down by 1.77%, or 4.80 points, and was trading at ₹266.15. Until now, the Indoco Remedies shares have traded within a range of ₹288 and ₹263.10. The traded volume for Indoco Remedies stock stood at 4.53 lakh shares, with the company’s market cap at ₹2,499 crore. The shares have their 52-week high at ₹355 and their 52-week low at ₹190.

Investor Takeaway For Indoco Remedies

Indoco Remedies reported weak financial results for the quarter ending September 30, 2025. While revenue increased by 8.8%, other key metrics remained under pressure, with a net loss and negative EPS weighing on investor sentiment. This has led to a decline in the stock price. However, as the company reduced its losses compared to previous quarters, investors remain hopeful for a return to profitability in the near future.

REF: https://nsearchives.nseindia.com/corporate/INDOCO_06112025114254_ResultSE.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations

Desktop BannerMobile Banner
Invest Anytime, Anywhere
Play StoreApp Store
Open Free Demat Account Online

By signing up I certify terms, conditions & privacy policy